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Summary
Objectives
The DSM-5 classifies depressive and anxiety disorders accord-
ing to clinical symptoms and assesses possible correlations with 
a medical condition, use of psychoactive or pharmacological 
drugs, or substance abuse. The objective of the present review 
is to overview the main depressive and anxiety disorders ac-
cording to the classification of the DSM-5 and to present the 
primary pharmacological and non-pharmacological treatments, 
with particular emphasis on the problem of compliance.
Methods
Literature review of recent years on depressive disorders and anxiety 
disorders was carried out following publication of the DSM-5 (2013).
Results
In the DSM-5, depressive disorders include disruptive mood 
dysregulation, major depressive disorder, persistent depressive 
disorder, premenstrual dysphoric disorder, depressive disorder 
induced by substances/drugs, and depressive disorder due to 
other medical conditions. The common characteristic of these 
conditions is the presence of sad, empty, or irritable mood, 
which together with specific cognitive and somatic symptoms 
leads to significant distress or impairment in functioning. The 
anxiety disorders recognised in the DSM-5 include separation 
anxiety disorder, selective mutism, specific phobia, social anxi-
ety disorder, panic disorder, agoraphobia, generalised anxiety 
disorder, anxiety disorder induced by substances/drugs and 
anxiety disorder due to another medical condition. All the dis-
orders share characteristics of excessive fear and anxiety cor-
related with behavioural alterations. In anxiety disorders, the 
stimulus, external or internal, produces a disproportionate anx-
ious reaction that is a source of intense distress or significant 
impairment of functioning. Pharmacological therapy alone, psy-
chotherapy alone, or the combination of both are efficacious in 
the treatment of depression, generalised anxiety disorder, panic 
attacks and insomnia. It is important to involve the patient in the 
therapeutic course through adequate communication and infor-
mation about time to therapeutic response and possible side ef-
fects. SSRIs (selective serotonin reuptake inhibitors) and SNRIs 
(serotonin-norepinephrine reuptake inhibitors) are first-choice 
agents in the treatment of depression, with demonstrated ef-
ficacy and safety. A benzodiazepine can be used in the first 4 
weeks of therapy for depression in the presence of significant 
symptoms of anxiety, in panic disorder and insomnia to obtain 
rapid improvement in symptoms. In the treatment of depressive 
disorders, compliance is important to achieve the objectives of 
antidepressant therapy. In recent years, significant progress has 
been made in identification of risk factors for poor compliance 
and development of a variety of strategies aimed at increasing 
adherence to therapy, especially in improving communication, 
patient education, dose optimisation and scheduled follow-up.
Conclusions
In treatment of depressive and anxiety disorders, therapeutic 
choice should consider patient preferences and must be decid-
ed together with the patient. Compliance is an important aspect 
that determines the success of treatment.
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The DSM-5 and clinical utility 
G. Maina, V. Salvi
Introduction: the DSM-5 in clinical practice
The Diagnostic and Statistical Manual of Mental Dis-
orders (DSM-5) is likely the most well-known and used 
diagnostic reference in psychiatry. Its descriptive and 
nontheoretical nature make it easy to use, and no spe-
cific theoretical training is needed to use it. In the DSM-5, 
psychiatric disorders are grouped into broad categories 
(such as psychotic disorders, depressive disorders, anxi-
ety disorders, etc.) within which the individual disorders 
are described. Each disorder is diagnosed on the basis of 
grouping of symptoms. To allow a diagnosis of mental 
disorder, a particular group of symptoms must be pres-
ent, which are related to impairment of functioning and/ 
or to significant discomfort. For many disorders, such as 
depressive disorders and anxiety disorders, ‘essential’ 
clinical features are distinguished from those caused by 
a concomitant medical condition or use of drugs or psy-
choactive substances.
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early childhood, also considering the strong association 
with later development of these disorders in adulthood. 
Major depressive disorder is characterised by the pres-
ence of episodes of persistently depressed mood and/or 
a diminished ability to experience pleasure, associated 
with at least five of the following symptoms: significant 
changes in appetite or weight, insomnia or hypersomnia, 
psychomotor agitation or retardation, weakness and easy 
fatigue, feelings of worthlessness or guilt, decreased con-
centration and memory impairment, thoughts of death. 
Symptoms must be present daily for at least 2 weeks, and 
depressed mood must be present for most of the time. 
Major depressive disorder is often recurrent and charac-
terised by episodes throughout life. Onset is usually be-
tween the ages of 20 and 30 years and is up to 3 times 
more frequent in women. It Italy, about 8-10% of the 
general population is affected.
Persistent depressive disorder is defined by its chronic 
course, characterised by the presence of persistently low 
mood for at least 2 years and associated with two or more 
of the following symptoms: poor or increased appetite, 
insomnia or hypersomnia, low energy and fatigue, low 
self-esteem, difficulty in concentrating and feelings and 
beliefs of hopelessness. Persistent depressive disorder 
has a prevalence of 2-3%, is more frequent in late ado-
lescence or early adulthood and often associated with 
personality disorders and substance abuse. Premenstrual 
dysphoric disorder has phasic fluctuations and appears 
in the week prior to the menstrual cycle. It tends to re-
solve during the first days of menstruation. The disorder 
is characterised by marked affective lability, associated 
with deflected and irritable mood, increased sensitivity 
to rejection and tendency to interpersonal conflicts. It is 
associated with changes in appetite and sleep, lethargy 
and fatigue, and physical symptoms such as bloating or 
tension, muscle and joint pain. Its prevalence is about 
1.3-1.8%.
Depressive disorder due to substances/drugs is charac-
terised by the presence of low mood and loss of inter-
ests that appear during or shortly after intoxication or 
discontinuation of the responsible agent, or during ex-
posure to a drug. It cannot be diagnosed in cases of de-
pressive symptoms lasting more than 1 month after the 
discontinuation of the substance/drug. Various abused 
substances, such as alcohol, opioids, sedative drugs, co-
caine or other stimulants, and hallucinogens, can induce 
depressive symptoms. Regarding the association between 
drugs and depression, depressive symptoms are associ-
ated with treatment with interferon-α, corticosteroids, in-
terleukin-2, GnRH, mefloquine, contraceptive implants 
that release progesterone and cardiovascular drugs such 
as methyldopa, clonidine, propranolol and sotalol. A re-
cent study on the reporting of drug-related adverse events 
The diagnostic course in clinical practice
When applied to depressive disorders and anxiety disor-
ders, two phases are primarily used for diagnosis in the 
DSM-5:
1. classify the disorder based on objective psychologi-
cal examination and patient-reported signs and symp-
toms;
2. evaluate if the symptoms may be correlated with a 
medical condition, use of psychoactive or pharmaco-
logical drugs, or substance abuse.
The first phase involves listening to subjective experienc-
es of the patient together with psychological examina-
tion. By grouping symptoms, the disorder can be defined. 
The second phase involves assessing for potential somat-
ic or exogenous causes of the psychic disorder. A variety 
of physical diseases can give rise to depression and anx-
iety. In some cases, depressive and anxious symptoms 
are characteristic of an underlying medical disease and 
present as the first manifestations of somatic disease. For 
example, loss of appetite, weight loss, fatigue and de-
pressed mood in older patients can be symptomatic of 
pancreatic cancer. In other cases, anxiety and restless-
ness associated with vegetative symptoms may be caused 
by onset of hyperthyroidism. In some cases, depression 
or anxiety may be related to a previously diagnosed dis-
ease, as in certain neurological and endocrine disorders. 
Lastly, depression and anxiety may be caused by phar-
macological treatment, a psychoactive drug, or by their 
discontinuation. Interactions between susceptibility and 
stressful events may generate diverse symptoms that are 
accurately classified in the DSM-5. The main clinical pic-
tures of depressive and anxiety disorders according to the 
DSM-5 are detailed below.
Depressive disorders in the DSM-5
Depressive disorders in the DSM-5 include disruptive 
mood dysregulation, major depressive disorder, persis-
tent depressive disorder, premenstrual dysphoric disor-
der, depressive disorder induced by substances/drugs 
and depressive disorder due to other medical conditions.
The common characteristic of these conditions is the 
presence of sad, empty, or irritable mood, which together 
with specific cognitive and somatic symptoms, leads to 
significant distress or impairment in functioning. Disrup-
tive mood dysregulation disorder is diagnosed in children 
who show severe and frequent outbursts of anger, which 
are grossly disproportionate to the triggering event, and 
associated with persistent irritated or sad mood that oc-
curs in different contexts, for example at home and at 
school. Diagnosis requires that the onset is before the age 
of 10 years. It is believed that this set of symptoms can 
constitute the expression of major depressive disorders in 
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tions to separation, even temporary, to attachment figures, 
especially parents. The disorder can even last into an adult 
age. Children with separation anxiety manifest the fear of 
losing their parents, refusal or reluctance to be alone, un-
willingness to go outside for fear that an external event 
might separate them from their parents, or to sleep away 
from home. Affected children may also report nightmares 
and somatic complaints. Separation anxiety disorder is di-
agnosed if three or more of the following symptoms are 
present for at least 4 weeks, or for 6 months in adults. In 
Italy, 2% of children suffer from separation anxiety disor-
der, with frequent onset at preschool age.
Selective mutism is diagnosed in children who do not 
speak in certain social situations, for example at school, 
which is related to high levels of social anxiety or exces-
sive shyness, and not to linguistic or intellectual deficits. 
Selective mutism is a rare disorder, with a prevalence of 
0.03-1%.
Specific phobias are characterised by excessive or unrea-
sonable fear of an object or situation, disproportionate 
to the actual danger, to which exposure leads to intense 
anxiety. The object or situation feared is actively avoided. 
Diagnosis of a specific phobia can be considered when the 
duration is at least 6 months. The most frequent phobias 
are those of animals (spiders, insects, dogs, etc.), natural 
(heights, storms, etc.), needles/blood and situations (aero-
planes, elevators, etc.). In Italy, about 6% of the popula-
tion suffers from a specific phobia over their lifetime, with 
onset normally around the age of 10 years. Social anxi-
ety disorder is characterised by fear of finding oneself in 
certain social situations. Some examples are speaking in 
a group of people, eating or drinking in public, or carry-
ing out specific tasks. An individual with social anxiety is 
afraid of failing in certain situations and then be judged, 
ridiculed, or criticised by others. For this reason, the per-
son frequently avoids contact in the feared social situation. 
Even in this case, symptoms must be present for at least 6 
months. In Italy, about 2% of the population suffers from 
in the UK from 1998-2011 found an association between 
depression and use of isotretinoin, rimonabant and var-
enicline. In Italy, there are no data on the prevalence of 
depressive disorders induced by substances/drugs, while 
in the US it has been estimated that the prevalence is 
0.26%.
Lastly, depressive disorder due to other medical condi-
tions can be diagnosed when depressive symptoms are 
the direct pathophysiological consequence of another 
medical condition. In some cases, the association be-
tween an underlying disease and depression is very 
strong, and common pathophysiological links have been 
demonstrated in the two conditions. This is the case with 
neurological conditions such as stroke, Parkinson’s and 
Huntington’s diseases, cranial trauma and multiple scle-
rosis as well as with endocrinopathies such as Cushing’s 
disease and hypothyroidism. In other cases, if the onset of 
depression is a response to stress related to an underlying 
disease, it is more correct to diagnose adjustment disor-
der with depressed mood.
Anxiety disorders in the DSM-5
Anxiety disorders share the characteristics of excessive fear 
and anxiety and related behavioural alterations. In anxi-
ety disorder, the stimulus, external or internal, produces 
a disproportionate anxiety that is the source of intense 
distress or significant impairment of functioning. Another 
characteristic of anxiety disorders is anxious anticipation, 
or rising levels of concern and tension at the approach of 
a feared situation, and avoidance of stimuli or situations 
that trigger anxiety, with further limitations in functioning.
The anxiety disorders recognised in the DSM-5 include 
separation anxiety disorder, selective mutism, specific 
phobia, social anxiety disorder, panic disorder, agorapho-
bia, generalised anxiety disorder, anxiety disorder induced 
by substances/drugs and anxiety disorder due to another 
medical condition. Separation anxiety disorder is diag-
nosed in children who have disproportionate anxious reac-
TABLE I. 
Depressive and anxiety disorders in the DSM-5.
Depressive disorders Anxiety disorders
Disruptive mood dysregulation disorder
Major depressive disorder
Persistent depressive disorder
Premenstrual dysphoric disorder
Depressive disorder induced by substances/drugs
Depressive disorder due to another medical condition
Separation anxiety disorder
Selective mutism
Specific phobia
Social anxiety disorder
Panic disorder
Agoraphobia
Generalised anxiety disorder
Anxiety disorder induced by substances/drugs
Anxiety disorder due to another medical condition
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social anxiety disorder over the course of a lifetime, with 
onset generally at the start of adolescence at around 13 
years.
Panic disorder is diagnosed in cases of recurrent or unex-
pected manic. Panic attack is a sudden episode of intense 
anxiety and discomfort, which reaches a peak in a few 
minutes and is associated with somatic symptoms such 
as palpitations, sweating, trembling, shortness of breath, 
choking sensation, chest pain, nausea, dizziness, numb-
ness, fear of going crazy, or dying. In panic disorder, at-
tacks are usually followed by the constant worry that they 
can recur or by concern about the consequences of at-
tacks. Patients often actively avoid situations that can trig-
ger the attacks, for example driving or visiting crowded 
places. Panic disorder is frequently associated with agora-
phobia, or the fear of being in situations where it is difficult 
or embarrassing to escape in case of a panic attack: classi-
cally feared situations are being in crowded places (public 
transport, cinemas, supermarkets), open spaces, being in a 
queue of cars or people, or being outside the home alone. 
Finding oneself in the feared situation frequently triggers 
a panic attack, which is the reason for which such situa-
tions are avoided in individuals with agoraphobia. Panic 
disorder usually appears in a young adult age and is more 
frequent in young women, with a frequency that is about 
twice that in men. In Italy, the lifetime prevalence of panic 
disorder is 1.6%, and 1.2% for agoraphobia.
Generalised anxiety disorder is diagnosed in cases of ex-
cessive anxiety and worry related to a large number of daily 
activities. The worry of having to carry out such activities, 
controlled with difficulty, is associated with at least three 
of the following symptoms: constant restlessness, easy 
fatigue, difficulty in concentrating, muscle tension, inter-
rupted or unsatisfactory sleep. On average, the disorder 
begins around the age of 30 years, although it frequently 
has onset in adolescence or older age. In Italy, the life-
time prevalence of generalised anxiety disorder is 1.9%. 
Anxiety disorder due to substances/drugs is defined by the 
presence of anxiety or panic attacks that occur during or 
shortly after intoxication or withdrawal from a substance, 
or during exposure to a drug. It cannot be diagnosed if 
the anxiety symptoms persist more than one month after 
discontinuation of the substance/drug. Several substances 
cause symptoms of anxiety: caffeine, cannabis, cocaine, 
amphetamines and other stimulants. Even exposure to 
drugs, such as salbutamol, sympathomimetics, insulin, 
thyroid hormones, L-Dopa and corticosteroids, can trigger 
anxiety symptoms. In addition, abstinence from alcohol, 
opioids, anxiolytics and especially benzodiazepines is fre-
quently related to anxiety symptoms.
Depressive disorder due to other medical conditions can 
be diagnosed when depressive symptoms are the direct 
pathophysiological consequence of another medical con-
dition. Pathologies of the endocrine system and metabolic 
conditions can cause anxiety and panic attacks, for ex-
ample hyperthyroidism, hypoglycaemia, pheochromocy-
toma, Cushing’s disease, vitamin B12 deficiency and por-
phyria. Even cardiopulmonary conditions, such as heart 
failure, pulmonary oedema, asthma and some arrhythmias 
can cause anxiety disorder.
Conclusions
The use of a diagnostic manual to define mental disorders 
in defined categories has many advantages, such as sim-
ple classification of patient experiences in well-defined 
clinical pictures and ease of communication with col 
leagues. Finally, the availability of validated treatments 
for individual disorders allows, not only for the specialist 
but for the general practitioner, to establish an effective 
treatment, which in some cases can fully resolve referred 
symptoms. 
TABLE II.
Drugs that can induce depressive and anxiety disorders.
Depressive disorders Anxiety disorders
Interferon α-β 
Corticosteroids 
Interleukin-2 
GnRH
Contraceptive implants that release 
progesterone
Cardiovascular (methyldopa, clonidine, 
propranolol, sotalol)
Mefloquine
Isotretinoin
Rimonabant
Varenicline
Corticosteroids 
Salbutamol 
Sympathomimetics 
Insulin
Thyroid hormones 
L-Dopa
TABLE III. 
Medical conditions that can cause depression and anxiety 
disorders.
Depressive disorders Anxiety disorders
Stroke
Parkinson’s disease
Huntington’s disease
Head injuries
Multiple sclerosis
Cushing’s disease
Hypothyroidism
Hyperthyroidism
Hypoglycaemia
Pheochromocytoma
Cushing’s disease
Vitamin B12 deficiency
Porphyria
Cardiovascular disease
(heart failure, atrial fibrillation)
Pulmonary diseases (pulmonary 
embolism, asthma)
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symptoms seen in 30% to 65% of cases. In other words, 
considering the entire population treated for major de-
pression, it is possible to affirm that:
• 20-30% achieve remission;
• 20-30% show a reduction of 50% in depressive 
symptoms without achieving complete remission 
(HAM-D > 7);
• 10-15% have a partial response, with 25-50% reduc-
tion in symptoms;
• 20-30% are non-responsive to therapy, with < 25% 
reduction in symptoms;
• in addition, 10-30% of the entire population does not 
respond to multiple pharmacotherapies and psycho-
therapies, and these subjects are at high risk of mor-
bidity and mortality.
Scientific evidence suggests that depression is much 
more disabling and resistant to treatment the longer it 
continues over time, and that a chronic course and/or 
highly recurrent disorder is associated with an increased 
risk of substance abuse, physical illness, suicide risk and 
social difficulties 4. Despite these considerations, to date 
clear and definitive criteria have not been identified for 
choice of optimal initial therapy or to substitute or modify 
ineffective or partially effective therapy. Research is hin-
dered by the wide variability of clinical presentations of 
depression, which is in part also responsible for incorrect 
or delayed recognition of the disease.
The main goals of treatment are:
• eliminate depressive symptoms;
• reduce or eliminate associated impairment;
• improve the quality of life and psychosocial functioning;
• prevent relapses and recurrences.
The objectives of initial treatment of major depression is 
remission of symptoms and improvement of the quality 
of life and psychosocial functioning. For initial treatment 
of a patient with mild-moderate depression there are 
several therapeutic strategies that involve the use of an-
tidepressants alone, psychotherapy alone or combined 
antidepressant/psychotherapy. Randomised trials have 
shown that combined antidepressant/psychotherapy is 
more effective than either of the individual approaches 
alone 5. Notwithstanding, additional studies have indi-
cated that pharmacological therapy or psychotherapy 
alone are also valid choices; moreover, the efficacy of 
the two therapies is comparable. It is important to de-
cide on the therapeutic course together with the patient, 
whose preferences can influence choice of therapy. In 
addition, complete evaluation of the patient must also 
include all aspects that could interfere with the thera-
peutic objective (previous therapies, comorbidities and 
psychosocial stressors). For patients with mild-moder-
ate depression, treatment with SSRIs is recommended 
as first-line; these recommendations are based on the 
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Pharmacological  
and non-pharmacological treatment
M. Mauri, C. Cargioli
Data from the international literature have shown 
that the majority of patients with major depression 
are treated by a general practitioner (GP) 1. GPs more 
frequently prescribe SSRIs and SNRIs than tricyclic 
antidepressants and monoamine oxidase inhibitors 
(MAO-I) 2; moreover, it has been demonstrated that the 
use of antidepressants is effective in improving symp-
toms in primary care settings 3. The OsMed report from 
2013 documented that SSRIs represent a first choice in 
terms of costs among drugs that act on the CNS in re-
imbursed treatment regimens, and are the most widely 
prescribed; however, data from HealthSearch 2011 re-
ported that only 35.4% of patients in whom a problem 
with depression has been identified are prescribed an 
antidepressant.
The use of drugs that act through multiple pathways 
seems to be even more valid in borderline pathologies 
and in pathologies within the spectrum of comorbidity. 
Thus, given the documented efficacy of many drugs clas-
sified as ‘antidepressants’ on anxiety symptoms, when 
dealing with an anxious-depressive condition, these 
drugs may be useful for ‘anti-depressive’ pharmacologi-
cal treatment. Clinical experience has shown that many 
depressed patients do not respond or show only partial 
response to antidepressants, with complete remission of 
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demonstrated efficacy and better tolerability of SSRIs 6. 
SNRIs (e.g. venlafaxine, duloxetine), atypical antide-
pressants (e.g. bupropion, mirtazapine) and serotonin 
modulators (e.g. trazodone) can be used as alternatives 
to an SSRI.
Tricyclics and MAO-Is are not recommended as first-line 
treatment due to their poorer safety profile and increased 
incidence of adverse events. A meta-analysis in 2011 
showed that there is no evidence in the choice of a sec-
ond-generation SSRI in terms of improvement of symp-
toms (Tables I, II) 7.
Pharmacological treatment of depression should con-
sider critical aspects. First, the severity of depression, for 
which antidepressants show significant benefits over pla-
cebo, has not been clearly defined. In general, the more 
severe the symptoms the greater the benefits of treatment. 
Antidepressants are nonetheless normally recommended 
as first-choice treatment in patients in whom depression 
is at least of moderate intensity. Secondly, there is large 
variability in tolerability, for which an individualised ap-
proach is useful in the attempt to find the best drug at 
the best dose, combining adequate clinical response with 
the lowest number of adverse effects. In the choice of 
an antidepressant, it is thus necessary to consider factors 
related to treatment (efficacy, tolerability, safety, formula-
TABLE I. 
Antidepressant drugs, initial dose and therapeutic dose.
Drug Initial dose 
(mg)
Therapeutic 
dose (mg)
SSRI
Citalopram 20 20-40
Escitalopram 10 10-20
Fluoxetine 20 20-60
Fluvoxamine 50 50-200
Paroxetine 20 20-40
Sertraline 50 50-200
SNRI
Duloxetine 30-60 30-120
Venlafaxine 37,5-75 75-375
Atypical antidepressants
Buproprion 150 300
Mirtazapine 15 15-45
Serotonin modulators
Trazodone 100 200-500
TABLE II.
Adverse effects of the main antidepressants (adapted from http://tmedweb.tulane.edu/pharmwiki/doku.php/antidepressant_side_ 
effects).
Drug Anticholinergic Drowsiness Insomnia/ 
agitation
Orthostatic 
hypotension
QTC Gastrointestinal 
toxicity
Weight 
gain
Sexual 
dysfunction
SSRI
Citalopram 0 0 1+ 1+ 1+ 1+ 1+ 3+
Escitalopram 0 0 1+ 1+ 1+ 1+ 1+ 3+
Fluoxetine 0 0 2+ 1+ 1+ 1+ 1+ 3+
Fluvoxamine 0 1+ 1+ 1+ 0-1+ 1+ 1+ 3+
Paroxetine 1+ 1+ 1+ 2+ 0-1+ 1+ 2+ 4+
Sertraline 0 0 2+ 1+ 0-1+ 2+ 1+ 3+
SNRI
Duloxetine 0 0 2+ 0 0 2+ 0 3+
Venlafaxine 0 1+ 2+ 0 1+ 2+ 0 3+
Atypical antidepressants
Bupropion 0 0 2+ 0 1+ 1+ 0 0
Mirtazapine 1+ 4+ 0 0 1+ 0 4+ 1+
Serotonin modulators
Trazodone 0 4+ 0 3+ 2+ 3+ 1+ 1+
Other strategies to treat depression, especially treatment-resistant depression, include electroconvulsive therapy (ECT), transcranial magnetic 
stimulation (TMS), vagal nerve stimulation (VNS) and deep brain stimulation (DBS).
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tion, costs, availability) and the patient (clinical picture, 
somatic comorbidities, individual response and tolerabil-
ity, previous response to therapy).
For initial treatment, a drug must be chosen that can be 
tolerated by the patient and that allows achieving a thera-
peutic dose with good adherence to therapy; the role of 
the GP is important in informing the patient about possi-
ble adverse effects and adequately communication with 
patients so that therapy will not be interrupted. It also 
minimises patient distrust of pharmacological treatment. 
Initial improvement of symptoms can be observed at 2-4 
weeks after therapy is initiated; the patient must under-
stand that effects are not immediate. Before considering 
a treatment inefficacious, a trial period of 6-12 weeks 
should be used.
While behaviour towards the use of drugs is measur-
able, since data is available (number of prescriptions, 
consumption, costs), it is more difficult to analyse the 
“prescribing” behaviour of psychotherapeutic treatment. 
As outlined in the following paragraphs, guidelines em-
phasise the use of psychotherapy in treatment of patients 
with depression and anxiety disorders; both specialists 
and GPs need to keep several considerations in mind:
• accessibility to psychotherapy within the healthcare 
system is limited and therefore the patient’s willing-
ness to bear costs will affects its use;
• “psychotherapy” does not exist, but rather a series 
of psychotherapeutic approaches that are specific 
for treatment of various disorders; the wide range 
available creates confusion for GPs about the cor-
rect approach;
• from the above considerations, such approaches may 
be underutilised and/or used incorrectly, exposing the 
patient to failure to achieve therapeutic goals, in ad-
dition to sustaining economic costs.
It is therefore desirable that in the future a more codi-
fied and collaborative care model can be adopted where 
the GP, psychiatric specialist and psychotherapist share 
the information needed to establish the correct course 
of treatment to reduce ‘split care’, which reduces the ef-
ficacy of treatment.
The psychotherapies that can be used for treatment of 
depression include:
• cognitive behavioural therapy (CBT);
• interpersonal psychotherapy;
• family and couple therapy;
• psychodynamic psychotherapy;
• supportive psychotherapy.
Although scientific studies have shown small differences 
in the effectiveness of different approaches for treatment 
of unipolar depression 8, CBT and interpersonal psycho-
therapy are most frequently used in the initial therapy of 
mild to moderate depression, as they represent the most 
widely studied and effective. Compared to pharmaco-
logical therapy, psychotherapy has been shown to be 
comparable in reducing the symptoms of depression 9. 
CBT aims to help patients identify recurring thoughts and 
dysfunctional patterns of reasoning and interpretation of 
reality in order to replace and/or supplement them with 
more functional beliefs.
In cases of severe depression at significant risk of sui-
cide, self-harm, or self-neglect, the therapeutic course 
should consider referral by the GP to a psychiatric spe-
cialist; such cases may require hospitalisation. Concern-
FIGURE 1. 
Considerations in patients who do not respond to antidepressant therapy (from Nemeroff, 2007, mod.) 10.
Psychiatric comorbidities
Correct diagnosis
Treatment-resistant 
patients
Concomitant medical conditions
Adequate duration of therapy
Adherence to therapy
Severity of disease
Appropriate 
pharmacological therapy
Adequate dose
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this subgroup and, in some cases, anxiety symptoms can 
worsen during the first few weeks of treatment with an-
tidepressants. Concomitant administration of anxiolytics 
and antidepressants should not continue for more than 4 
weeks; after this initial phase of treatment, the anxiolytic 
should be tapered gradually and slowly for at least 2-4 
weeks before discontinuation.
The use of combined therapies with a BDZ can rapidly 
improve anxiety symptoms, and also reduces the pos-
sible effects related to initiation of antidepressant ther-
apy. Nonetheless, it is important to remember that the 
use of BDZs is associated with possible risks such as loss 
of efficacy over time (tolerance), sedation, psychomotor 
impairment and increased risk of falling (especially in el-
derly). BDZs should also be used with extreme caution in 
patients with a history of addiction (alcohol and/or sub-
ing long-term treatment, the following should always be 
considered:
• a single episode of depression should be treated for at 
least 6-9 months after remission;
• the risk of recurrence of depression increases after 
each episode;
• patients suffering from several episodes require main-
tenance treatment for many years.
Patients with depression who present with significant 
anxiety symptoms are common in clinical practice; 
some studies have reported the co-presence of anxiety 
and depression in > 50% of patients. Treatment of pa-
tients with comorbid anxiety and depression includes 
the use of anxiolytics to control symptoms; in the acute 
phase of depression with significant anxiety symptoms, 
antidepressants have been shown to be less efficacious in 
TABLE III.
Potential advantages and disadvantages of the main drug classes in clinical use.
Advantages Disadvantages 
Tricyclic 
antidepressants
High clinical efficacy (reuptake of serotonin 
and/or norepinephrine)
Increased incidence of side effects (interaction with 
β-adrenergic, muscarinic and histamine H1 receptors)
Antidepressant SSRI Particularly effective on psychic symptoms; 
reduce any anxious concomitant depressive 
symptoms; low potential for abuse
Less effective on somatic symptoms; variability in patient re-
sponse; delay in onset of action; sexual dysfunction; weight 
gain; withdrawal symptoms; drug interactions (CYP 2D6)
Antidepressant SNRI Broad spectrum of therapeutic activity 
Safety: reduced risk of toxicity in overdose 
Tolerability: less incidence of discontinua-
tion for side effects
Related to activity of serotonin receptors:
• gastrointestinal disturbances (nausea, vomiting, weight 
loss)
• headache
• sexual dysfunction (anorgasmia, decreased libido)
• anxiety, tremor, nervousness, agitation
• physical dependence “discontinuation syndrome” 
Related to noradrenergic receptor activity:
• hypertension (at high dose
Trazodone Anxiolytic and antidepressant efficacy with 
sedative effects (improved sleep); few anti-
cholinergic effects; minimal sexual side ef-
fects
Orthostatic hypotension; sedation (sleepiness); cardiovascu-
lar problems: interaction with antihypertensives (may facili-
tate onset of hypotension and CNS depressant effects, e.g. 
clonidine); ventricular arrhythmias and torsades de pointes
Bupropion Effective on lethargy, fatigue, apathy, drowsi-
ness, reduction of interest and anhedonia
Minimal effects on body weight and sexual 
function
Initial increase in anxiety levels; lowers threshold seizure
Mirtazapine Improved sleep; no agitation, no sexual side 
effects, no nausea, no headaches
Increased weight gain
Agomelatine Increases release of dopamine and norepi-
nephrine but not 5-HT in the frontal cortex, 
with favourable effects on restoration of cor-
rect circadian rhythm
Possible worsening of liver function tests
Benzodiazepine Especially effective for somatic symptoms; 
rapid onset of action; reproducible response 
and good tolerability
Less effective in psychological symptoms; possible addic-
tion with the use of high long-term dosages; cognitive and 
psychomotor impairment; drug interactions (CYP 3A4)
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stance abuse) and a history of difficult adherence to anti-
depressant therapy: both categories of patients are at risk 
of discontinuing the antidepressant and only continuing 
treatment with the BDZ, since it has a faster onset of ac-
tion. The use of on-demand BDZs is not recommended: 
such an approach does not appear to be effective from a 
therapeutic standpoint; repeated access to a rescue dose 
can reinforce psychological dependence on the drug.
Several aspects should be considered in patients with 
panic disorder:
• the initial dose of an SSRI corresponds to half of the 
initial dose used for major depression and gradual ti-
tration is highly recommended to reduce the possibil-
ity of exacerbation of symptoms in the first days of 
therapy, in consideration of the greater sensitivity of 
these patients to the stimulating effects of SSRIs 11;
• the use of a BDZ should be considered in the first 
weeks of therapy to achieve rapid improvement of 
symptoms (the clinical benefits of an SSRI alone are 
obtained in 4-6 weeks), and to minimise possible side 
effects of initiation of therapy with an SSRI.
In patients who complain of insomnia, drug treatment 
is an effective and economical approach to treat a 
large number of patients. BDZs have demonstrated ef-
ficacy on insomnia, reducing latency and increasing 
the total sleep time. BDZs are not all equal as they 
have different affinities for the different subpopulations 
of receptors and different half-lives; all have the same 
dose-dependent effects (anxiolytic action, hypnotic-
sedative, muscle relaxant, anticonvulsant). The choice 
between various BDZs depends primarily on the type 
of insomnia to be treated (initial, middle, end). When 
indicated, it is preferable to use a short or intermedi-
ate half-life BDZ to reduce the possibility of adverse 
events and complications, such psychomotor functions 
and daytime sedation.
In insomnia associated with depression, therapeutic in-
tervention may include the use of antidepressants asso-
ciated with hypnotic drugs, with varying effectiveness 
depending on the severity of depression and type of 
insomnia. Antidepressants can have a positive effect on 
insomnia during the course of depression or may have 
an “activating” effect that disturbs sleep. Some SSRI and 
SNRI antidepressants can disrupt sleep; in order to mi-
nimise effects on sleep the dose should be taken in the 
morning and at an antidepressant dosage.
Take-home messages
• Pharmacological therapy with antidepressants alone, 
psychotherapy alone, or a combination of both treat-
FIGURE 2. 
Side effects (adapted from Racagni G, Popoli M. Int Clin Psychopharmacol 2010;25:117-31).
Traditional
antidepressants
H1 antagonists
Sedation/somnolence
Weight gain
Postural hypotension
Priapism Dizziness 
Reflex tachycardia
Dry mouth 
Urinary retention 
Activation effects 
CV
Tremor
Gastrointestinal 
disturbances 
Activation effects
Nausea
Blurred vision 
Dry mouth 
Constipation 
Sinus tachycardia 
Urinary retention
Memory impairment
5-HT2
receptor antagonists
Sexual dysfunction
Side effects of activation
Psychomotor activation 
Psychosis
5-HT3 receptor 
antagonists
5-HT
reuptake 
inhibitors
NE reuptake 
inhibitors
Alpha2 
antagonists
Alpha1 
antagonists
ACH antagonists
DA reuptake inhibitors
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Antidepressants and compliance
A. Rossi
Introduction
Compliance is defined as the extent to which the be-
haviour of a person, in terms of taking medication or 
lifestyle changes, corresponds to a medical prescrip-
tion  1. Therefore, compliance should not be under-
stood simply as “lack of taking a medication”, since 
it involves a wide range of behavioural and lifestyles 
changes, each of which plays an important role in the 
overall success of treatment. As a result, unsatisfactory 
compliance can be related to failure to comply with 
outpatient visits, not performing monitoring tests, early 
treatment discontinuation, or rejection or modification 
of the prescribed treatment 2.
For a more interactive, collaborative and proactive ap-
proach, many researchers and clinicians have suggested 
the use of the term ‘adherence’ or ‘alliance’, rather than 
‘compliance’ 3. However, at present, the terms adher-
ence and compliance are used interchangeably. Tradi-
tionally, rates of discontinuation during treatment are 
considered the best index of non-adherence.
In the field of psychiatry, Cramer and Rosenheck 4 re-
ported that adherence to pharmacological therapy in 
patients with psychiatric disorders is less than patients 
with physical diseases, with a rate of non-adherence in 
the former that varies from 24 to 90% with a mean level 
of non-adherence of around 60%. In particular, in treat-
ment of depressive disorders compliance is important 
to achieve all the objectives of antidepressant therapy, 
which include resolution of symptoms, restore normal 
functioning and prevent relapses and recurrent epi-
sodes 5. If therapy is adhered to, about 70% of patients 
with depression can be successfully treated by pharma-
cotherapy 6, but in spite of the availability of efficacious 
antidepressants, the rates of recurrence for depression 
ments are efficacious in treatment of depression, gen-
eralised anxiety disorder, panic attacks and insomnia.
• The choice of treatment should take into account pa-
tient preferences and should be decided together with 
the patient.
• It is important to involve the patient in the therapeu-
tic process through adequate communication that 
informs the patient, especially regarding the time to 
therapeutic response after the start of treatment (phar-
macological and/or psychotherapeutic) and possible 
onset of common adverse effects when an antidepres-
sant is used.
• SSRIs and SNRIs are the first choice for treatment 
of depression and have demonstrated efficacy and 
safety even when used in the setting of general 
medicine.
• It is recommended to use the lowest effective thera-
peutic dose of an SSRI or SNRI at the beginning of 
therapy for depression. Initial improvement begins at 
4 weeks after the initiation of therapy.
• In panic attack disorder, the starting dose of an SSRI 
or SNRI is one-half that normally used in treatment 
of depression, and should be gradually titrated over 
2-4 weeks.
• A BDZ can be used in the first 4 weeks of therapy 
for depression in the presence of significant anxiety 
symptoms, in panic attack disorder and insomnia in 
order to achieve rapid improvement in symptoms.
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approaches 80% 7, and therapeutic failure is frequent, 
from 40 to 60% 8.
Moreover, guidelines for treatment of depression are 
not always followed and non-adherence rates are high, 
with 28% of patients discontinuing treatment with anti-
depressants within the first month and 44% discontinu-
ing within three months after initiation of therapy. Bull 
et al.  9 have reported that up to 68% of patients with 
depression stop taking antidepressants after only three 
months of treatment.
In randomised clinical trials, discontinuation rates are 
between 20 and 40%, with the most frequent reason for 
discontinuation represented by “side effects”, while in 
naturalistic studies the rates are higher, usually 50-60% 
within 10 weeks, with the category ‘feel better’ cited 
as the most frequent reason 10. In addition, the overall 
rate of adherence decreases by 2.5% for each month of 
treatment with antidepressants, as reported Demytten-
aere et al. (2008) 11.
In recent years, considerable progress has been made 
in the identification of risk factors of non-compliance to 
therapy with antidepressants and in developing strate-
gies to assess and improve adherence, which can lead 
to better therapeutic results and decrease the morbidity 
of depressive disorders
How to assess compliance
Compliance to pharmacological therapy is usually classi-
fied as “good” (75-100% of doses), “average” (25-75% of 
doses), “poor” (0-25% of doses). “Hyper-compliance” is 
defined as the intake of >100% of doses. Such behaviour 
is often established by the patient in the belief that this 
will accelerate the onset of action or increase its effec-
tiveness 12. Leite et al. 13 stated that adherence to treat-
ment should be defined as use of the prescribed medica-
tion for at least 80% of the time, taking into account time 
of day, dosage and total duration of treatment.
Quantifying non-compliance and its consequences is not 
straightforward. Demyttenaere 12 identified two method-
ological problems: the first is inherent to the reliability of 
study results, while the second involves the instruments 
used. The author holds that compliance is greater in clini-
cal studies than in clinical practice, and that it is even 
greater in clinical studies that investigate adhesion to 
therapy. It was also stated that, in the field of adherence 
to therapy, simple measurement tools are not accurate, 
and accurate ones are not easy to use.
According to Farmer, tools to measure adherence to 
pharmacological therapy can be divided into direct and 
indirect  14. The first provide evidence that the patient 
has taken the drug and include: detection of the drug 
or its metabolite in a biological fluid (usually blood or 
urine), detection of a biological marker co-administered 
with the drug (or placebo) and direct patient observa-
tion. The presence of a drug or its metabolite in a bio-
logical fluid provides confirmation that the patient has 
received a dose of medication within a certain period 
before testing. The presence of the drug in a test, how-
ever, does not ensure good compliance, and its absence 
does not always correspond to non-compliance. Most 
patients may have similar serum levels of the target 
drug, but may have taken the drug in a different way; se-
rum or urine levels cannot quantify the mode in which 
the patient has taken the drug or detect fluctuations of 
compliance over time. Finally, inter-individual varia-
tions in metabolism and in the volume of distribution 
influence the level of medication regardless of adher-
ence, making it hard to measure. Biological markers are 
non-toxic, stable compounds that are easily identifiable, 
which can be added to the drug to be monitored; they 
provide qualitative evidence that the patient has recent-
ly received a dose of drug. Lastly, in closely monitored 
clinical trials patients can be observed directly while 
taking the drug. This method is not always applicable 
or infallible as patients can deliberately pretend to swal-
low the medication.
The majority of the assessment methods used, however, 
are indirect and include self-reporting by the patient, 
counting of tablets, revision of the prescription registers 
and electronic monitoring devices.
Accounts given by patients on how they take medi-
cation is the easiest means of evaluating compliance. 
Patient interviews are generally considered to be a re-
liable method, even if the method of self-report used 
and the way in which it is used must be considered, 
given that patient responses may be influenced by both 
communication with the physician and the specific 
wording of questions. Several researchers have tried to 
correct such shortcomings by developing standardised 
self-report questionnaires to measure adherence to a 
treatment regimen, including the Morisky-Green test 
(MGT) 15 and Brief Medication Questionnaire (BMQ) 16. 
For patients with depressive disorder, Demyttenaere et 
al. 17 developed the Antidepressant Compliance Ques-
tionnaire (ADCQ), which evaluates attitudes and beliefs 
of patients about depression and treatment with antide-
pressants. Finally, Gabriel and Violato 18 developed the 
Antidepressant Adherence Scale (AAS), which queries 
the patient’s knowledge and attitudes towards depres-
sive disorder as determinants of compliance.
Counting tablets involves simple counting of the num-
ber of doses that the patient has not taken, and com-
paring the doses given to those prescribed. In recent 
years, the use of computerised prescription records 
has increased utilisation of prescription adjustments, 
which allow researchers to investigate early discon-
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with the presence of more pronounced cognitive deficits. 
Furthermore, cognitive impairment can also affect patient 
insight. Lee et al. 23 examined the role of insight and ad-
herence and showed that patients with more severe de-
pression tend to have a greater insight, but that the latter is 
not associated with better adherence. Many studies have 
investigated the correlation between patient demograph-
ics and compliance. Despite the general assumption that 
older patients are less compliant than younger individu-
als, this relationship is not yet firmly established 24, and it 
seems that other related features, such as old age, social 
isolation and polypharmacy, are predictive of lower com-
pliance. The notion that older patients are less compliant 
is supported by a study by van Geffen et al. 25 in which 
interruption of treatment was twice as high in patients 60 
years and older.
In contrast, Brown et al. 26 reported that older patients are 
more adherent to therapy than younger patients. Looking 
in detail at the results of van Geffen et al. 25 and Brown 
et al. 26, it would seem, however, that older patients were 
more likely to question the use of drug therapy before 
trying it, whereas they may be more motivated to stay 
on therapy once it is initiated. Demyttenaere 11 found 
that non-compliance is higher in women than in men 11 
and, similarly, Brown et al. 26 observed that men are more 
compliant women.
Kessing et al. 27 investigated the attitudes and beliefs 
of depressed bipolar patients and towards antidepres-
sants. They reported that a large number of patients, 
especially those over 40 years, generally had a nega-
tive view of antidepressants, unclear ideas regarding 
their influence and a critical vision of the doctor-pa-
tient relationship.
Even personality-related aspects are important predictors 
of compliance, and their identification can help in devel-
oping individualised treatment regimens. In 2004, Cohen 
et al. 28 investigated the relationship between personality 
characteristics, according to a 5-factor model, and com-
pliance to antidepressant treatment in 65 outpatients with 
major depressive disorder. They reported that extrover-
sion was a significant negative predictor of compliance, 
while the subdomain modesty was a positive predictor. 
In the same study, the authors showed that none of the 
socio-demographic or disease-related characteristics 
such as age, sex, or number of previous depressive epi-
sodes, correlated with compliance.
Another interesting aspect is the type of pharmacologi-
cal treatment that the patient receives and, above all, 
its dosage. Shigemura et al. 29, in a study on 1151 sub-
jects with major depressive disorder, observed that pa-
tients with daily monotherapy had greater adherence 
compared with bid or tid dosing, suggesting that a re-
duction in the frequency of administration improves 
tinuation of therapy and taking medicines in ways that 
it was not prescribed.
Finally, electronic monitoring devices, including the 
Medication Event Monitoring System (MEMS), contain a 
microprocessor that records the time and date on which 
the patient receives a dose of the drug. They are useful 
as they allow one to identify the voluntary deviations 
from the prescribed regimen and the effect of daily dis-
tribution of doses.
George et al. 19 compared four different methods for 
evaluation of compliance to determine the advantages 
and disadvantages. The following were used: patient 
self-report, counting tablets, MEMS and plasma assays 
of dothiepin and nordothiepin. The techniques were 
evaluated in 88 patients who initiated treatment with 
a tricyclic antidepressant in a GP setting. MEMS was 
the most informative technique and was considered 
to be the ‘gold standard’. The Morisky questionnaire 
was found to be a useful screening technique with a 
sensitivity between 72 and 84% for identification of 
low compliance and a specificity of 74.1% for good 
compliance (> 80%). As in previous studies, pill count 
was difficult and of questionable validity. Of the four 
methods, the least satisfactory was measurement of 
blood concentration.
Factors that influence compliance 
Adherence to antidepressant treatment is influenced by 
multidimensional factors. In agreement with most litera-
ture data, the aforementioned study by Demyttenaere et 
al. 10 showed that the most frequently reported reasons 
for discontinuation of therapy by patients are “feel bet-
ter” (55%, average time of discontinuation 11 weeks) 
and appearance of side effects (23%, average time 6.5 
weeks). However, several reasons were responsible for 
the discontinuation at different times over the course of 
the study.
The main factors influencing adherence are related to the 
characteristics of the disease, the patient, treatment and 
the doctor-patient relationship. Chronic, asymptomatic 
diseases that require long-term treatment, such as de-
pressive disorder, are associated with lower compliance: 
the longer the remission phase, the lower compliance to 
therapy 20. In addition, diseases in which the relationship 
between non-compliance and relapse is clear (e.g. dia-
betes) are associated with better compliance than those 
in which the relationship is less clear (e.g. depressive 
disorder) 21. Demyttenaere 11 highlighted that depression 
in itself can passively reduce adherence. In fact, patients 
often have memory problems, and may feel hopeless and 
have less motivation. Ayalon et al. 22, in a study of el-
derly patients, noted that interruption of treatment, and in 
particular unintentional interruption, is associated mainly 
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they were not informed. Moreover, if the possible side ef-
fects of the drug had been discussed, patients were more 
likely to continue therapy. These results clearly highlight 
the importance of the doctor-patient relationship in ad-
herence to therapy.
More recently, Tamburrino et al. 38 found that patients 
who are not satisfied with their physician tend to be less 
compliant, and especially among those who have felt 
that they had not been adequately informed about the 
side effects of treatment. Similar results were found in the 
study by Brown et al. 26, who reported that it is beneficial 
for physicians to discuss the possible side effects with pa-
tients and inform them about how to take their therapy. In 
general, patients who are very satisfied with their physi-
cian are more compliant 29.
How to improve compliance
Adequate education and active participation are funda-
mental to improve adherence during treatment in pa-
tients with depressive disorder. Interventions that target 
the patient, the physician and the structural aspects of 
care can potentially improve adherence and treatment 
outcomes. If the patient is well informed about the 
course of the disease, symptoms and prognosis, adher-
ence is better.
Several strategies have been developed to improve com-
pliance, including: improving communication, patient 
education, dose optimisation and scheduling of follow-
up visits. To improve doctor-patient communication, 
Cramer 39 proposed that the physician should discuss 
diagnosis and treatment with the patient, as well as the 
therapeutic plan chosen and timing of follow-up. Edu-
cation should include information about treatment and 
healthcare providers should offer supportive interven-
tions to patients and family members, while the treatment 
regimen should include reduction in the number of daily 
doses and number of drugs taken.
Even the problem of generic prescriptions may interfere 
with adhesion and should be discussed with the pa-
tient 40. As early as 1997, Demyttenaere 12 highlighted 
the importance of the doctor-patient relationship in this 
regard, stating that patients who perceive the physician 
as empathetic and disposed to diminish their worries 
are more compliant. In the previously-mentioned study 
by Ashton et al. 36, the authors concluded that compli-
ance can be promoted through better understanding of 
the expectations and desires of patients to therapy and 
by prescription of antidepressants associated with a low 
incidence of side effects.
Finally, in a systematic review assessing the effectiveness 
of interventions to improve compliance, Vergouwen et 
al. 41 noted that collaborative care interventions, tested 
in primary care settings, have shown significant improve-
adherence. The class of antidepressants had no signifi-
cant effect on adherence.
Even the formulation may affect compliance. The cur-
rently available antidepressants are typically formulated 
as tablets or capsules for oral administration; in some 
cases they are also available as an oral suspension and 
intravenous formulation. However, extended release 
formulations of fluoxetine, venlafaxine, bupropion and 
paroxetine are under development, which offer greater 
ease of use and improved adherence 30-32. Regarding the 
visual characteristics of the drug (e.g. form, size and 
colour), de Craen et al. 33 found that red, orange and 
yellow tablets are most appropriate for stimulant drugs, 
and that blue and green are better suited for sedatives. 
Buckalew et al. 34 reported that capsules are perceived 
as being more powerful than tablets and that the size 
of the capsule corresponds to perception of efficacy. In 
many studies, the appearance of side effects was a key 
cause of treatment discontinuation.
In an investigation by Bull et al. 35, 43% of patients who 
discontinued treatment within 3 months did so because 
of side effects. This proportion decreased to 27% in the 
second quarter of treatment, suggesting that patients who 
interrupt for side effects are more likely to do so at an 
early stage of therapy. Ashton et al. 36, even if they found 
that lack of efficacy was the most common reason for 
interruption, also stressed the central role of side effects, 
including loss of sexual interest, fatigue and lethargy, and 
significant weight gain.
Regarding the influence of the drug class on compli-
ance, data in the literature have given as much con-
sideration to effectiveness as to side effects of the two 
major classes of antidepressants currently in use (SSRIs 
and TCA). A meta-analysis 37 of 102 randomised con-
trolled clinical trials of SSRIs and TCAs found no sig-
nificant differences in efficacy between the two classes. 
However, although significant differences were seen in 
discontinuation rates, the clinical relevance of such dif-
ferences is unclear. Discontinuation rates between the 
two classes are similar, although SSRIs have a better tol-
erability profile.
Bull et al. 35 studied doctor-patient communication. Con-
sidering the availability of many well-tolerated antide-
pressants, the authors found that the rate of treatment in-
terruption cannot be explained solely by the appearance 
of side effects. Both physicians and patients compiled a 
questionnaire about the information that had been given 
to the patient on the antidepressant and duration of treat-
ment. Interestingly, 72% of doctors referred that they had 
advised the patient to continue treatment for at least 6 
months. In contrast, only 34% of patients remembered 
receiving such advice. The percentage of non-compli-
ance was three times greater for patients who thought 
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